Viking Thera (VKTX) Stock Price, Quote & News

Company Profile

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It develops VK5211, an orally available non-steroidal selectiv...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 704 4660

Website: www.vikingtherapeutics.com

Address:

9920 Pacific Heights Boulevard, Suite 350, San Diego, United States

jmartin795 Dec. 4 at 12:06 PM

$VKTX Got this off X. Streamlined phase 3

0 · Reply

himsssss Dec. 4 at 12:04 PM

$VKTX Looks faker than donalds trumps $2000 stimulus

1 · Reply

Wallst45 Dec. 4 at 11:41 AM

$VKTX fda meetings will not be revealed until completed with them. It’s scheduled to complete by end of December anytime

0 · Reply

EmSol Dec. 4 at 6:39 AM

$CAPR my next one to explode $VKTX, just need to wait

1 · Reply

HedgeAlerts Dec. 4 at 6:38 AM

Hedge Alert Live - Protect Your Portfolio Contract: $VKTX $35.00 Put · DEC 12, 2025 Exp Entry Price: $1.60 - $2.53 Exit Price Target: $3.79 Profit Margin: +137% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

DG20 Dec. 4 at 6:34 AM

$VKTX There is no other US based, ‘late stage’ pure play left in the GLP market. GPCR is making a small molecule GLP mono-agonist that’s a minimum of 12 months behind Vikings dual-agonist. More importantly, of the other big players that aren’t LLY zero of them have pipeline drugs that perform as well/well tolerated as SQ VK2735 (NVO, Roche, AMGN, ZEAL, PFE). Viking has tremendous scarcity value and we know that a minimum of 6 big pharma we’re pursuing MTSR prior to its buyout.

1 · Reply

Iightning Dec. 4 at 5:17 AM

1ightning® Premium Options Alert (Actionable) Ticker: $VKTX Contract: Dec 19 $35.5C Entry: 2.90 Exit: 3.63 Return: +25.45% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

LiquidThetaOptions Dec. 4 at 5:16 AM

💎 LiquidTheta® Live Actionable Trade Asset: $VKTX Contracts: $VKTX January 15, 2027 $38 Calls Scale in: $11.26- $13.76 Scale out: $43.79-$75.07 Profit Potential : 261% ROI Blended Join 💎 Here: https://liquidtheta.com

0 · Reply

ebringer Dec. 4 at 5:06 AM

$VKTX I may have heard today that Viking is in talks with several big pharma companies, and Viking is asking a lot for the company, but that is not scaring the interested parties off at all. Instead, many of them are very interested in additional data and are mainly concerned that Viking doesn't have long-term data on VK2735 efficacy and AEs to support the ask. However, Viking can supposedly somehow provide longer-term data to interested parties early H2 2026 - significantly earlier than the VANQUISH-1 phase 3 should end. Make up your own mind on this.

1 · Reply

Wallst45 Dec. 4 at 4:05 AM

$VKTX lot of chatter on FDA meeting

0 · Reply

Prediction: This Undervalued Stock Could Compete With Novo Nordisk by 2029

Nov 25, 2025, 4:05 PM EST - 8 days ago

Viking Therapeutics to Participate at the Piper Sandler 37th Annual Healthcare Conference

Nov 22, 2025, 9:20 AM EST - 11 days ago

2 Healthcare Stocks for Beginner Investors With a 20-Year Time Horizon

PFE

Nov 21, 2025, 1:58 PM EST - 12 days ago

3 Weight-Loss Drug Stocks To Consider For 2026

LLY NVO

Nov 21, 2025, 4:31 AM EST - 13 days ago

3 Mid-Cap Growth Stocks That Have Mammoth Long-Term Potential

CRSP ELF

Nov 19, 2025, 6:05 AM EST - 15 days ago

Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon.

CRSP

Nov 19, 2025, 4:48 AM EST - 15 days ago

Viking Therapeutics, Inc. (VKTX) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 19, 2025, 2:55 AM EST - 15 days ago

Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-1 Trial of VK2735

Nov 18, 2025, 2:11 PM EST - 15 days ago

5AM Venture Just Dumped Its Viking Stake—Smart Call or Missed Opportunity?

Nov 18, 2025, 6:45 AM EST - 16 days ago

2 No-Brainer Healthcare Stocks to Buy Now

PFE

Nov 10, 2025, 4:45 AM EST - 24 days ago

2 Monster Stocks in the Making

AXSM

Nov 9, 2025, 6:55 AM EST - 25 days ago

Is There a Future for Viking Therapeutics?

Nov 6, 2025, 7:05 AM EST - 4 weeks ago

Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program in Presentation at ObesityWeek® 2025

Nov 5, 2025, 10:01 AM EST - 4 weeks ago

Druckenmiller's Viking Trade Just Hit A Golden Cross — And A Sweet 36% Gain

Nov 5, 2025, 5:15 AM EST - 4 weeks ago

Here's Why Shares in Viking Therapeutics Shot Higher in October

Nov 4, 2025, 8:10 PM EST - 4 weeks ago

Billionaire Stanley Druckenmiller Dropped Nvidia and Palantir Stock and Is Piling into 2 Stocks Set to Win in One of the Decade's Hottest Growth Markets.

LLY

Nov 4, 2025, 4:05 PM EST - 4 weeks ago

Viking Therapeutics to Participate at Upcoming Investor Conferences

Nov 3, 2025, 4:45 AM EST - 4 weeks ago

Prediction: The Next Eli Lilly Might Already Be Trading Under $50

Nov 2, 2025, 9:20 AM EST - 4 weeks ago

Should You Buy Viking Therapeutics Before Nov. 5?

Oct 31, 2025, 4:55 AM EDT - 4 weeks ago

3 Promising Growth Stocks That Are Down Around 60% From Their Highs

CAVA FIG

Oct 29, 2025, 4:05 PM EDT - 5 weeks ago

Viking Therapeutics to Highlight Clinical Data from VK2735 Obesity Program in Presentations at ObesityWeek® 2025

Oct 23, 2025, 2:36 PM EDT - 5 weeks ago

Here's Why This Obesity Drug Company's Share Price Soared Today

Oct 23, 2025, 10:42 AM EDT - 5 weeks ago

Viking Therapeutics Q3 Earnings: What We Learned (And Why We Should Keep Faith)

Oct 23, 2025, 10:05 AM EDT - 5 weeks ago

Viking Therapeutics: The Prime Target In The Obesity Gold Rush

Oct 22, 2025, 7:33 PM EDT - 6 weeks ago

Viking Therapeutics, Inc. (VKTX) Q3 2025 Earnings Call Transcript

Oct 22, 2025, 4:05 PM EDT - 6 weeks ago

Viking Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Oct 21, 2025, 7:05 AM EDT - 6 weeks ago

Viking Therapeutics Announces Initiation of VK2735 Maintenance Dosing Clinical Trial in Patients with Obesity

Oct 17, 2025, 4:15 AM EDT - 6 weeks ago

Eli Lilly vs. Viking Therapeutics Stock: Which Is the Best Growth Opportunity, According to Wall Street?

LLY

Oct 16, 2025, 7:45 AM EDT - 7 weeks ago

Did Viking Therapeutics Just Say "Checkmate" to Eli Lilly?

Oct 15, 2025, 4:05 PM EDT - 7 weeks ago

Viking Therapeutics to Report Financial Results for Third Quarter 2025 on October 22, 2025

Oct 13, 2025, 10:15 AM EDT - 7 weeks ago

Down 44%, Should You Buy the Dip on Viking Therapeutics?

Oct 9, 2025, 1:37 PM EDT - 7 weeks ago

Why Shares in Viking Therapeutics Surged This Week

Oct 4, 2025, 9:44 AM EDT - 2 months ago

Viking Therapeutics: A Speculative Buy

Sep 30, 2025, 9:15 AM EDT - 2 months ago

Why This Beaten-Down GLP-1 Stock Could Be a Steal

Sep 28, 2025, 2:00 PM EDT - 2 months ago

Viking Therapeutics: Overdue For Gains

Sep 23, 2025, 1:53 PM EDT - 2 months ago

Viking Therapeutics, Inc. (VKTX) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript

Sep 22, 2025, 1:55 PM EDT - 2 months ago

Viking Therapeutics, Inc. (VKTX) Q4 2023 Earnings Call Transcript

Sep 19, 2025, 4:40 AM EDT - 2 months ago

Prediction: Viking Therapeutics Stock Will Double in Value Within the Next 12 Months

Sep 11, 2025, 3:43 PM EDT - 2 months ago

Prediction: After a Tough Summer for Healthcare Stocks, These 2 Companies Can Make a Comeback

NVO

Sep 8, 2025, 5:43 PM EDT - 3 months ago

Viking Therapeutics, Inc. (VKTX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 7, 2025, 11:14 AM EDT - 3 months ago

Think It's Too Late to Buy This Leading Biotech Stock? Here's Why There's Still Time.

Sep 5, 2025, 4:10 AM EDT - 3 months ago

Down 34%, Should You Buy the Dip on Viking Therapeutics?

Sep 4, 2025, 9:00 AM EDT - 3 months ago

Prediction: These 2 Biotech Stocks Could Double in the Next 5 Years

AXSM

Aug 28, 2025, 6:42 PM EDT - 3 months ago

Why Viking Therapeutics Stock Popped Nearly 4% Today

Aug 27, 2025, 10:00 AM EDT - 3 months ago

Billionaire Stanley Druckenmiller Just Bought the Dip on This Beaten-Down GLP-1 Stock (Hint: It's Not Eli Lilly or Novo Nordisk)

Aug 27, 2025, 7:30 AM EDT - 3 months ago

Why Is Viking Therapeutics Stock Crashing, and Is It a Buying Opportunity?

Aug 26, 2025, 6:15 AM EDT - 3 months ago

Viking Therapeutics: What's Next?

Aug 24, 2025, 8:45 AM EDT - 3 months ago

2 Biotech Stocks That Could Soar 21% and 245% According to Wall Street's Top Analysts

REGN

Aug 23, 2025, 6:57 AM EDT - 3 months ago

Viking: Still On Track, But The Compass Needs Recalibration

Aug 22, 2025, 10:21 AM EDT - 3 months ago

Here's Why Shares in Viking Therapeutics Crashed This Week

jmartin795 Dec. 4 at 12:06 PM

$VKTX Got this off X. Streamlined phase 3

0 · Reply

himsssss Dec. 4 at 12:04 PM

$VKTX Looks faker than donalds trumps $2000 stimulus

1 · Reply

Wallst45 Dec. 4 at 11:41 AM

$VKTX fda meetings will not be revealed until completed with them. It’s scheduled to complete by end of December anytime

0 · Reply

EmSol Dec. 4 at 6:39 AM

$CAPR my next one to explode $VKTX, just need to wait

1 · Reply

HedgeAlerts Dec. 4 at 6:38 AM

0 · Reply

DG20 Dec. 4 at 6:34 AM

1 · Reply

Iightning Dec. 4 at 5:17 AM

1ightning® Premium Options Alert (Actionable) Ticker: $VKTX Contract: Dec 19 $35.5C Entry: 2.90 Exit: 3.63 Return: +25.45% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

LiquidThetaOptions Dec. 4 at 5:16 AM

0 · Reply

ebringer Dec. 4 at 5:06 AM

1 · Reply

Wallst45 Dec. 4 at 4:05 AM

$VKTX lot of chatter on FDA meeting

0 · Reply

BioRich Dec. 4 at 3:53 AM

$XBI $PFE $LLY Looking for a sanity check... If a Bio company issues their Topline trial/primary P2b endpoint data and then 3 months later add this note to a presentation (no mention to it, no PR, just snuck it into a presentation/publication), is there reason for concern? "One patient randomized to the placebo group received 1.2mg pemvidutide (drug) but was included in the placebo group" Thanks in advance. $ALT $VKTX

1 · Reply

biolover Dec. 4 at 3:36 AM

$VKTX FDA let novo move oral amycretin from phase 1 straight to 3. Can’t believe how cautious this Bl is. Will be shocking if FDA asks for phase 2B. Same molecule in 2 large phase 3 now.

1 · Reply

biolover Dec. 4 at 3:31 AM

$VKTX Also “ oral phase 3 or 2B start by mid 2026 “ meeting scheduled with FDA later this month

0 · Reply

biolover Dec. 4 at 3:26 AM

$VKTX From Piper “VKTX’s novel amylin program (~1:1 amylin:calcitonin) is on track for IND submission in 1Q26. Preclinical data suggest a competitive profile, demonstrating competitive weight-loss efficacy at lower doses vs dual agonists, with the potential to develop both SC and oral formulations.”

1 · Reply

bavariaron Dec. 4 at 2:08 AM

$VKTX ** Akero $5.2B Deal Approved ** “Shareholders of Akero Therapeutics, Inc. (NASDAQ:AKRO) voted Tuesday to approve the company’s pending acquisition by Novo Nordisk A/S, according to a statement based on a U.S. Securities and Exchange Commission filing.” Note: Akero has also reported positive data from its Phase 2b trials for efruxifermin, showing a reduction in fibrosis and disease progression risk in patients with metabolic dysfunction-associated steatohepatitis (MASH). Deal expected to close by YE 2025. https://m.investing.com/news/sec-filings/akero-therapeutics-shareholders-approve-acquisition-by-novo-nordisk-93CH-4388937?ampMode=1 VKTX VK2809

0 · Reply

DueDiligence9601 Dec. 4 at 1:20 AM

$VKTX Seeing chatter on an FDA meeting but no confirmation. Still

0 · Reply

MoneyGroupLLC Dec. 4 at 1:04 AM

Enter: $VKTX Calls Strike Price: $36 Expiry Date: DEC 26 2025 Buy in Price: $2.24 - $3.70 Sell Price: $4.32 Profit : +93% (Turn every $1 into $1.93) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

Wal187 Dec. 4 at 12:51 AM

$VKTX Crazy amount of puts being sold on GPCR. We could be looking at a perfect storm of catalyst to end the year.

2 · Reply

Linar264 Dec. 4 at 12:46 AM

$VKTX GUIDANCE WELCOME: FDA oral meeting to hopefully skip P2b to P3 How long after the meeting (9th or 12th December) would $VKTX be given the outcome of FDA decision. Is correct to assume they have submitted the request and the meeting it to present thier case for approval to go to P3 ? What is the process and considerations here ?

1 · Reply

barbaresqo Dec. 4 at 12:46 AM

$VKTX sold. GLTA.

1 · Reply

KetCopyPaste Dec. 4 at 12:43 AM

$VKTX I mean what’s the worst that could happen on great news? 40% haircut? 😂 we got this!

0 · Reply

KetCopyPaste Dec. 4 at 12:35 AM

$VKTX Alright I’m calling it. Quiet. Controlled. Loaded. Every push builds a little more pressure under the surface. Shorts have no idea what they’re sitting on. We’re walking into a stretch where anything can spark the next leg. Not a specific headline. Not a date. Just the simple reality that this chart has been coiling for weeks and the range is tighter than it’s ever been. Stocks don’t sit like this unless something big is building behind the scenes. Look at the trend. Look at the higher lows. Look at how fast this thing recovers every time they try to dunk it. That isn’t weakness. That’s a monster warming up. Good night. Rest well. Tomorrow is another step closer to the kind of move people pretend they “called” after it already happened. I’m already here. Bulls are already planted. And the setup is cleaner than it’s ever been. Let’s see who’s awake when this thing finally decides to stretch. Onwards!

0 · Reply

Market Cap	3.83B
Revenue (ttm)	0.00
Net Income (ttm)	-109.96M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	2,759,200
Avg Vol	4,300,238
Day's Range	N/A - N/A
Shares Out	113.04M
Stochastic %K	56%
Beta	0.65
Analysts	Strong Sell
Price Target	$89.82